



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION

A-834735 Degradant

Item No. 14165

CAS Registry No.: 2244599-90-2

Formal Name: 3,3,4-trimethyl-1-[1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl]-4-penten-1-one

MF: C₂₂H₂₉NO₂

FW: 339.5


Purity: ≥95%

UV/Vis.: λ_{max}: 213, 246, 304 nm

Supplied as: A solution in methanol

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

A-834735 (Item No. 11163) is an indole-derived cannabinoid (CB) with a 3-tetramethylcyclopropylmethanone substituent. It acts as a full agonist at both the central CB₁ and peripheral CB₂ receptors in rat with K_i values of 4.6 and 0.31 nM, respectively, and EC₅₀ values of 12 and 0.21 nM, respectively.¹ A-834735 readily crosses the blood-brain barrier, dose-dependently reversing thermal hyperalgesia without adverse side effects in a rat neuropathic pain model.¹ A-834735 degradant is a common impurity observed during GC-MS analysis of samples containing A-834735. The opened ring of the degradant is presumed to be produced during heating of A-834735. This structure gives rise to a prominent fragment ion that is 15 amu greater than the base peak of A-834735. This pattern is consistent with McLafferty rearrangement of the degradant which does not occur with the parent compound.²

References

- Chin, C.-L., Tovcimak, A.E., Hradil, V.P., et al. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. *Br. J. Pharmacol.* **153**(2), 367-379 (2008).
- McLafferty, F.W. Mass spectrometric analysis. Molecular rearrangements. *Anal. Chem.* **31**(1), 82-87 (1959).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/25/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 - USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM